Astragaloside IV inhibits renal tubulointerstitial fibrosis by blocking TGF-β/Smad signaling pathway in vivo and in vitro

Experimental Biology and Medicine

Volumn 239, Issue 10, 2014, Pages 1310-1324

  Wang, Li ^a   Chi, Yang Feng ^a   Yuan, Ze Ting ^a   Zhou, Wen Chao ^a   Yin, Pei Hao ^a   Zhang, Xue Mei ^b   Peng, Wen ^a   Cai, Hui ^c,d  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

Astragaloside IV; Renal tubulointerstitial fibrosis; TGF Smad signaling pathway; Unilateral ureteral obstruction

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ASTRAGALOSIDE IV; COLLAGEN TYPE 2; COLLAGEN TYPE 3; CONNECTIVE TISSUE GROWTH FACTOR; ENALAPRIL; FIBRONECTIN; LACTATE DEHYDROGENASE; SMAD PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; ASTRAGALOSIDE A; SAPONIN; SMAD7 PROTEIN, RAT; TRITERPENE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FIBROBLAST; FUNCTIONAL DISEASE; GENE SILENCING; GENETIC TRANSFECTION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY FUNCTION TEST; MALE; MTT ASSAY; NONHUMAN; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR BLOCKING; RENAL PROTECTION; RENAL TUBULOINTERSTITIAL FIBROSIS; RNA INTERFERENCE; UPREGULATION; UREA NITROGEN BLOOD LEVEL; URETER OBSTRUCTION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DISEASE MODEL; DRUG EFFECTS; FIBROSIS; GENE EXPRESSION PROFILING; KIDNEY; KIDNEY DISEASES; PATHOLOGY; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

RATTUS;

ANIMALS; DISEASE MODELS, ANIMAL; FIBROSIS; GENE EXPRESSION PROFILING; KIDNEY; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; RATS, SPRAGUE-DAWLEY; SAPONINS; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRITERPENES;

EID: 84921765718     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/1535370214532597     Document Type: Article

References (46)

1. Chatziantoniou C, Dussaule JC. Insights into the mechanisms of renal fibrosis: is it possible to achieve regression? Am J Physiol Renal Physiol 2005;289:F227-34
2. Li R, Wang Y, Liu Y, Chen Q, Fu W, Wang H, Cai H, Peng W, Zhang X. Curcumin inhibits transforming growth factor-beta1-induced EMT via PPARgamma pathway, not Smad pathway in renal tubular epithelial cells. PLoS One 2013;8:e58848
3. Zeisberg M, Kalluri R. The role of epithelial-to-mesenchymal transition in renal fibrosis. J Mol Med (Berl) 2004;82:175-81
4. Zeisberg M, Neilson EG. Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol 2010;21:1819-34
5. Yang J, Liu Y. Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am J Pathol 2001;159:1465-75
6. Liu N, Tolbert E, Pang M, Ponnusamy M, Yan H, Zhuang S. Suramin inhibits renal fibrosis in chronic kidney disease. J Am Soc Nephrol 2011;22:1064-75
7. Fukasawa H, Yamamoto T, Togawa A, Ohashi N, Fujigaki Y, Oda T, Uchida C, Kitagawa K, Hattori T, Suzuki S, Kitagawa M, Hishida A. Down-regulation of Smad7 expression by ubiquitin-dependent degradation contributes to renal fibrosis in obstructive nephropathy in mice. Proc Natl Acad Sci U S A 2004;101:8687-92
8. Schnaper HW, Hayashida T, Poncelet AC. It's a Smad world: regulation of TGF-beta signaling in the kidney. J Am Soc Nephrol 2002;13:1126-8
9. Ebisawa T, Fukuchi M, Murakami G, Chiba T, Tanaka K, Imamura T, Miyazono K. Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation. J Biol Chem 2001;276:12477-80
10. Kavsak P, Rasmussen RK, Causing CG, Bonni S, Zhu HT, Thomsen GH, Wrana JL. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol Cell 2000;6:1365-75
11. Nakao A, Afrakhte M, Moren A, Nakayama T, Christian JL, Heuchel R, Itoh S, Kawabata M, Heldin NE, Heldin CH, ten Dijke P. Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature 1997;389:631-5
12. Chung ACK, Huang XR, Zhou L, Heuchel R, Lai KN, Lan HY. Disruption of the Smad7 gene promotes renal fibrosis and inflammation in unilateral ureteral obstruction (UUO) in mice. Nephrol Dial Transpl 2009;24:1443-54
13. Liu GX, Li YQ, Huang XR,Wei L, Chen HY, Shi YJ, Heuchel RL, Lan HY. Disruption of Smad7 promotes ANG II-mediated renal inflammation and fibrosis via Sp1-TGF-beta/Smad3-NF-kappaB-dependent mechanisms in mice. PLoS One 2013;8:e53573
14. Lan HY, Mu W, Tomita N, Huang XR, Li JH, Zhu HJ, Morishita R, Johnson RJ. Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model. J Am Soc Nephrol 2003;14:1535-48
15. Li JH, Zhu HJ, Huang XR, Lai KN, Johnson RJ, Lan HY. Smad7 inhibits fibrotic effect of TGF-beta on renal tubular epithelial cells by blocking Smad2 activation. J Am Soc Nephrol 2002;13:1464-72
16. Liu SF, Chang SY, Lee TC, Chuang LY, Guh JY, Hung CY, Hung TJ, Hung YJ, Chen PY, Hsieh PF, Yang YL. Dioscorea alata attenuates renal interstitial cellular fibrosis by regulating Smad- and epithelialmesenchymal transition signaling pathways. PLoS One 2012;7:e47482
17. Tang LX, He RH, Yang G, Tan JJ, Zhou L, Meng XM, Huang XR, Lan HY. Asiatic acid inhibits liver fibrosis by blocking TGF-beta/Smad signaling in vivo and in vitro. PLoS One 2012;7:e31350
18. Qiu LH, Xie XJ, Zhang BQ. Astragaloside IV improves homocysteineinduced acute phase endothelial dysfunction via antioxidation. Biol Pharm Bull 2010;33:641-6
19. Zhao J, Yang PY, Li F, Tao L, Ding H, Rui YC, Cao ZW, Zhang WD. Therapeutic effects of astragaloside IV on myocardial injuries: multitarget identification and network analysis. PLoS One 2012;7:e44938
20. Gui D, Huang J, Guo Y, Guo J, Chen Y, Xiao W, Liu X, Wang N. Astragaloside IV ameliorates renal injury in streptozotocin-induced diabetic rats through inhibiting NF-kappaB-mediated inflammatory genes expression. Cytokine 2013;61:970-7
21. Gui D, Huang J, Liu W, Guo Y, Xiao W, Wang N. Astragaloside IV prevents acute kidney injury in two rodent models by inhibiting oxidative stress and apoptosis pathways. Apoptosis 2013;18:409-22
22. Tan SF, Wang GF, Guo YP, Gui DK, Wang NS. Preventive effects of a natural anti-inflammatory agent, astragaloside IV, on ischemic acute kidney injury in rats. Evid-Based Complement Altern 2013;2013:284025
23. Zheng R, Deng YY, Chen YP, Fan JM, Zhang MH, Zhong YF, Zhu R, Wang L. Astragaloside IV attenuates complement membranous attack complex induced podocyte injury through the MAPK pathway. Phytother Res 2012;26:892-8
24. Gui DK, Guo YP,Wang F, LiuW, Chen JG, Chen YF, Huang JH,Wang N. Astragaloside IV, a novel antioxidant, prevents glucose-induced podocyte apoptosis in vitro and in vivo. PLoS One 2012;7:e39824
25. Qi W, Niu J, Qin Q, Qiao Z, Gu Y. Astragaloside IV attenuates glycated albumin-induced epithelial-to-mesenchymal transition by inhibiting oxidative stress in renal proximal tubular cells. Cell Stress Chaperon. Epub ahead of print 2013
26. Meng LQ, Tang JW, Wang Y, Zhao JR, Shang MY, Zhang M, Liu SY, Qu L, Cai SQ, Li XM. Astragaloside IV synergizes with ferulic acid to inhibit renal tubulointerstitial fibrosis in rats with obstructive nephropathy. Br J Pharmacol 2011;162:1805-18
27. Ikezumi Y, Suzuki T, Hayafuji S, Okubo S, Nikolic-Paterson DJ, Kawachi H, Shimizu F, Uchiyama M. The sialoadhesin (CD169) expressing a macrophage subset in human proliferative glomerulonephritis. Nephrol Dial Transpl 2005;20:2704-13
28. Huang LH, Haylor JL, Hau Z, Jones RA, Vickers ME, Wagner B, Griffin M, Saint RE, Coutts IGC, El Nahas AM, Johnson TS. Transglutaminase inhibition ameliorates experimental diabetic nephropathy. Kidney Int 2009;76:383-94
29. Li Y, Sun Y, Liu F, Sun L, Li J, Duan S, Liu H, Peng Y, Xiao L, Liu Y, Xi Y, You Y, Li H, Wang M, Wang S, Hou T. Norcantharidin inhibits renal interstitial fibrosis by blocking the tubular epithelial-mesenchymal transition. PLoS One 2013;8:e66356
30. Park SH, Choi MJ, Song IK, Choi SY, Nam JO, Kim CD, Lee BH, Park RW, Park KM, Kim YJ, Kim IS, Kwon TH, Kim YL. Erythropoietin decreases renal fibrosis in mice with ureteral obstruction: role of inhibiting TGF-beta-induced epithelial-to-mesenchymal transition. J Am Soc Nephrol 2007;18:1497-507
31. Fragiadaki M, Mason RM. Epithelial-mesenchymal transition in renal fibrosis $ evidence for and against. Int J Exp Pathol 2011;92:143-50
32. Moon JA, Kim HT, Cho IS, Sheen YY, Kim DK. IN-1130, a novel transforming growth factor-beta type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy. Kidney Int 2006;70:1234-43
33. Bottinger EP, Bitzer M. TGF-beta signaling in renal disease. J Am Soc Nephrol 2002;13:2600-10
34. Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 2004;15:1-12
35. Abreu JG, Ketpura NI, Reversade B, De Robertis EM. Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat Cell Biol 2002;4:599-604
36. Phanish MK, Wahab NA, Colville-Nash P, Hendry BM, Dockrell ME. The differential role of Smad2 and Smad3 in the regulation of profibrotic TGFbeta1 responses in human proximal-tubule epithelial cells. Biochem J 2006;393:601-7
37. Qi W, Twigg S, Chen X, Polhill TS, Poronnik P, Gilbert RE, Pollock CA. Integrated actions of transforming growth factor-beta1 and connective tissue growth factor in renal fibrosis. Am J Physiol Renal Physiol 2005;288:F800-9
38. Li BX, Tang YT,WangW, Xie YY,Wang NS, Yuan QJ, Zhang FF, Peng ZZ, Hu GY, Tao LJ. Fluorofenidone attenuates renal interstitial fibrosis in the rat model of obstructive nephropathy. Mol Cell Biochem 2011;354:263-73
39. Yokoi H, Mukoyama M, Nagae T, Mori K, Suganami T, Sawai K, Yoshioka T, Koshikawa M, Nishida T, Takigawa M, Sugawara A, Nakao K. Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis. J Am Soc Nephrol 2004;15:1430-40
40. Chung AC, Zhang H, Kong YZ, Tan JJ, Huang XR, Kopp JB, Lan HY. Advanced glycation end-products induce tubular CTGF via TGF-betaindependent Smad3 signaling. J Am Soc Nephrol 2010;21:249-60
41. Zhang C, Meng X, Zhu Z, Liu J, Deng A. Connective tissue growth factor regulates the key events in tubular epithelial to myofibroblast transition in vitro. Cell Biol Int 2004;28:863-73
42. Yokoi H, Sugawara A, Mukoyama M, Mori K, Makino H, Suganami T, Nagae T, Yahata K, Fujinaga Y, Tanaka I, Nakao K. Role of connective tissue growth factor in profibrotic action of transforming growth factorbeta: a potential target for preventing renal fibrosis. Am J Kidney Dis 2001;38:S134-8
43. Lan HY. Smad7 as a therapeutic agent for chronic kidney diseases. Front Biosci 2008;13:4984-92
44. Itoh S, LandstromM, Hermansson A, Itoh F, Heldin CH, Heldin NE, ten Dijke P. Transforming growth factor beta1 induces nuclear export of inhibitory Smad7. J Biol Chem 1998;273:29195-201
45. Suzuki C, Murakami G, Fukuchi M, Shimanuki T, Shikauchi Y, Imamura T, Miyazono K. Smurf1 regulates the inhibitory activity of Smad7 by targeting Smad7 to the plasma membrane. J Biol Chem 2002;277:39919-25
46. Meng XM, Huang XR, Chung AC, Qin W, Shao X, Igarashi P, Ju W, Bottinger EP, Lan HY. Smad2 protects against TGF-beta/Smad3- mediated renal fibrosis. J Am Soc Nephrol 2010;21:1477-87